Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology · Ependymoma

Prognosis, Risk Stratification, and Life After Treatment

At a Glance

The long-term prognosis for ependymoma depends heavily on achieving a complete surgical removal (Gross Total Resection) and the tumor's specific molecular subtype. Survivorship requires ongoing MRI surveillance to monitor for recurrence and careful management of long-term side effects.

Understanding the long-term outlook for ependymoma has changed dramatically. While doctors once relied solely on the “grade” of the tumor, we now know that molecular subtype and the extent of resection (surgery) are the most powerful predictors of the future [1][2]. This shift allows for “risk stratification”—grouping patients by their specific risk level to ensure they receive the right amount of treatment.

Prognosis by Molecular Subtype

The molecular subgroup tells a story about how the tumor is likely to behave. While every patient is different, broad patterns have emerged across the major groups [2]:

  • Posterior Fossa (Back of Brain):
    • Group B (PFB): Generally has a more favorable outlook. Many patients with PFB tumors achieve long-term survival with surgery and radiation [2][3].
    • Group A (PFA): This group is more aggressive and has a higher risk of returning after treatment, requiring very close monitoring [4][5].
  • Supratentorial (Upper Brain):
    • YAP1-fused: These tumors often have an excellent prognosis, with some of the highest long-term survival rates in the ependymoma family [2][6].
    • ZFTA-fused: These are more common and tend to be more aggressive than the YAP1 type, often requiring intensive treatment [2].

The Impact of a “Clean” Surgery

Regardless of the molecular type, achieving a Gross Total Resection (GTR)—removing all visible tumor—remains the most critical factor for a positive outcome [7]. Patients who have a GTR generally experience significantly longer Progression-Free Survival (PFS), which is the amount of time the tumor stays away after treatment [8][9].

Life After Treatment: The Survivorship Journey

Completing treatment is a major milestone, but it is the beginning of a new phase of care. Survivorship involves monitoring for both the return of the tumor and the “late effects” of treatment.

1. Surveillance and “Scan Anxiety”

Regular MRI scans are the most effective way to catch a recurrence early, often before it causes any symptoms [10]. Detecting a return through a scheduled scan is linked to better survival outcomes than waiting for symptoms to appear [11]. Many families experience “scan anxiety”—a period of intense stress leading up to and following a scan. This is a common and valid emotional response; speaking with a counselor or support group can help manage these feelings [12].

2. Long-Term Side Effects

Survivors may face health challenges years after treatment ends [13].

  • Spinal Cord Recovery: For patients with spinal ependymomas, survivorship often involves extensive physical therapy. Long-term monitoring may be needed for mobility changes, chronic nerve pain, or issues with bowel and bladder control [14].
  • Cognitive Follow-up: For patients who receive brain radiation, it can affect processing speed, memory, and attention [15]. Regular neuropsychological evaluations are recommended to identify these issues early and provide school or workplace accommodations [16].
  • Endocrine Health: If the brain’s hormone centers (like the pituitary gland) were near the treatment area, survivors may need long-term monitoring for growth hormone or thyroid deficiencies [17].
  • Physical Health: Hearing loss or balance issues can occur, particularly after surgery or radiation in the posterior fossa [18].

Managing Recurrence

If an ependymoma returns, it is a significant challenge, but not one without options. Modern “salvage” therapy often involves a combination of re-surgery to achieve a second GTR and re-irradiation [8][19]. These approaches have successfully led to long-term survival in many patients, especially when the recurrence is localized to one spot [9][20]. Your team may also explore clinical trials for new drugs that target the tumor’s specific molecular weaknesses [21].

Common questions in this guide

How does my molecular subtype affect my ependymoma prognosis?
Your tumor's molecular subgroup is a strong predictor of how it will behave over time. For example, PFB and YAP1 subtypes generally have a more favorable long-term outlook, while PFA and ZFTA types tend to be more aggressive and require closer monitoring.
What is a Gross Total Resection and why is it important?
A Gross Total Resection means the surgeon was able to remove all of the visible tumor during your operation. Achieving this complete removal is the most critical factor for extending the amount of time the tumor stays away after treatment.
Why are regular MRI scans needed after ependymoma treatment?
Regular MRI scans are the best way to catch a returning tumor early, often before it causes any physical symptoms. Finding a recurrence during a scheduled scan is linked to better survival outcomes compared to waiting until symptoms develop.
What long-term side effects might I experience after brain tumor treatment?
Survivorship can bring late effects like cognitive changes, hearing loss, balance issues, or hormone deficiencies. Regular neuropsychological and physical evaluations help identify these issues early so you can get the right support and accommodations.
What happens if my ependymoma comes back?
While a recurrence is challenging, there are still effective treatment options available. Doctors often use salvage therapies, such as a second surgery or additional radiation, which can lead to long-term survival, especially if the returning tumor is in just one spot.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my (or my child's) specific molecular risk category based on the 2021 WHO classification?
  2. 2.How does the success of our initial Gross Total Resection (GTR) change our long-term prognosis?
  3. 3.What is the schedule for surveillance MRIs, and why is imaging preferred over waiting for symptoms?
  4. 4.Can we schedule a baseline neuropsychological evaluation to monitor cognitive health over the coming years?
  5. 5.If the tumor were to return, what would be the standard approach to 'salvage' therapy at this facility?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    The association between postoperative photon radiotherapy dose and disease control and salvage treatment in pediatric and adolescent ependymoma: a multi-institutional investigation.

    Liu KX, Salans M, Easwaran TP, et al.

    Journal of neuro-oncology 2025; (173(1)):167-177 doi:10.1007/s11060-025-04975-5.

    PMID: 39998722
  2. 2

    Ependymal Tumors: Overview of the Recent World Health Organization Histopathologic and Genetic Updates with an Imaging Characteristic.

    Soni N, Ora M, Bathla G, et al.

    AJNR. American journal of neuroradiology 2024; (45(11)):1624-1634 doi:10.3174/ajnr.A8237.

    PMID: 38844368
  3. 3

    Ependymal Tumors.

    Thomas AG, Chattopadhyay A, Dineen RA

    Neuroimaging clinics of North America 2026; (36(1)):69-83 doi:10.1016/j.nic.2025.08.008.

    PMID: 41274771
  4. 4

    Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues.

    Delgado-López PD, Corrales-García EM, Alonso-García E, et al.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019; (21(11)):1450-1463 doi:10.1007/s12094-019-02082-2.

    PMID: 30868390
  5. 5

    Delineation of molecular characteristics in pediatric PFA ependymoma involving rare osseous and pulmonary metastases: A case report and literature review.

    Zhou M, Wang L, Sun P, et al.

    Frontiers in oncology 2022; (12()):1001118 doi:10.3389/fonc.2022.1001118.

    PMID: 36457507
  6. 6

    Aggressive Supratentorial Ependymoma, RELA Fusion-Positive with Extracranial Metastasis: A Case Report.

    Kim SI, Lee Y, Kim SK, et al.

    Journal of pathology and translational medicine 2017; (51(6)):588-593 doi:10.4132/jptm.2017.08.10.

    PMID: 29161788
  7. 7

    Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy.

    Patteson BE, Baliga S, Bajaj BVM, et al.

    Neuro-oncology 2021; (23(1)):156-166 doi:10.1093/neuonc/noaa139.

    PMID: 32514542
  8. 8

    Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma.

    Gupta T, Maitre M, Gupta P, et al.

    Journal of neuro-oncology 2020; (147(2)):405-415 doi:10.1007/s11060-020-03434-7.

    PMID: 32072441
  9. 9

    Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma-a multi-institutional study.

    Mak DY, Laperriere N, Ramaswamy V, et al.

    Neuro-oncology advances 2021; (3(1)):vdab158 doi:10.1093/noajnl/vdab158.

    PMID: 34988448
  10. 10

    Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up.

    Massimino M, Barretta F, Modena P, et al.

    Journal of neuro-oncology 2018; (140(2)):457-465 doi:10.1007/s11060-018-2974-6.

    PMID: 30109673
  11. 11

    How long should survivors of pediatric medulloblastoma and ependymoma be screened for recurrence? A retrospective cohort study.

    Meulendijks TFC, Kaspers GJL, Ramaswamy V, et al.

    International journal of cancer 2025; (157(10)):2114-2123 doi:10.1002/ijc.70016.

    PMID: 40548641
  12. 12

    Longitudinal Psychological Distress After Malignant Brain Tumor Diagnosis: A Multilevel Analysis of Patients and Their Caregivers.

    Karger A, Kisić AM, Quente C, et al.

    Psycho-oncology 2025; (34(1)):e70064 doi:10.1002/pon.70064.

    PMID: 39794295
  13. 13

    The medical and functional burden of surviving childhood ependymoma: A population-based study in Ontario, Canada.

    Coltin H, Pequeno P, Liu N, et al.

    Pediatric blood & cancer 2024; (71(11)):e31275 doi:10.1002/pbc.31275.

    PMID: 39152641
  14. 14

    Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas.

    Liu T, Yang C, Deng X, et al.

    Neurosurgical review 2020; (43(5)):1351-1356 doi:10.1007/s10143-019-01150-z.

    PMID: 31473875
  15. 15

    Psychosocial Late Effects in Pediatric Cancer Survivors: A Report From the Children's Oncology Group.

    Bitsko MJ, Cohen D, Dillon R, et al.

    Pediatric blood & cancer 2016; (63(2)):337-43 doi:10.1002/pbc.25773.

    PMID: 26488337
  16. 16

    Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis.

    Götze H, Friedrich M, Taubenheim S, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2020; (28(1)):211-220 doi:10.1007/s00520-019-04805-1.

    PMID: 31001695
  17. 17

    The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review.

    DeVine A, Landier W, Hudson MM, et al.

    JAMA oncology 2025; (11(5)):544-553 doi:10.1001/jamaoncol.2024.6812.

    PMID: 39976936
  18. 18

    Complications following resection of primary and recurrent pediatric posterior fossa ependymoma.

    Malhotra AK, Nobre L, Ibrahim GM, et al.

    Journal of neurosurgery. Pediatrics 2024; (33(4)):367-373 doi:10.3171/2023.11.PEDS23364.

    PMID: 38241689
  19. 19

    Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma.

    Tsang DS, Murray L, Ramaswamy V, et al.

    Neuro-oncology 2019; (21(4)):547-557 doi:10.1093/neuonc/noy191.

    PMID: 30452715
  20. 20

    Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma.

    Tsang DS, Burghen E, Klimo P, et al.

    International journal of radiation oncology, biology, physics 2018; (100(2)):507-515 doi:10.1016/j.ijrobp.2017.10.002.

    PMID: 29229328
  21. 21

    Outcomes after first relapse of childhood intracranial ependymoma.

    Tsai JW, Manoharan N, Alexandrescu S, et al.

    Pediatric blood & cancer 2021; (68(8)):e28930 doi:10.1002/pbc.28930.

    PMID: 33565268

This page provides educational information about ependymoma prognosis and survivorship. Always discuss your specific molecular subtype, prognosis, and long-term care plan with your specialized oncology team.

Get notified when new evidence is published on Ependymal tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.